A61K 2039/572
Cytotoxic response
Official title: {cytotoxic response}
A61K2039/572 (Cytotoxic response) appears on 1,511 US grants and 2,854 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,511
- Published applications
- 2,854
- Assignees
- 1,050
- Inventors
- 4,381
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 2 |
| 2003 | 4 | 1 |
| 2004 | 1 | 8 |
| 2005 | 1 | 7 |
| 2006 | 4 | 6 |
| 2007 | 0 | 8 |
| 2008 | 1 | 9 |
| 2009 | 8 | 20 |
| 2010 | 6 | 33 |
| 2011 | 10 | 31 |
| 2012 | 9 | 32 |
| 2013 | 18 | 50 |
| 2014 | 27 | 59 |
| 2015 | 46 | 83 |
| 2016 | 81 | 193 |
| 2017 | 59 | 212 |
| 2018 | 144 | 226 |
| 2019 | 168 | 225 |
| 2020 | 163 | 262 |
| 2021 | 191 | 269 |
| 2022 | 141 | 270 |
| 2023 | 103 | 266 |
| 2024 | 114 | 229 |
| 2025 | 137 | 217 |
| 2026 | 70 | 136 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Live-attenuated flaviviruses with heterologous antigens22 Sep 2026US 12,741,991 B2Katholieke Universiteit Leuven
- Modified antibodies15 Sep 2026US 12,734,208 B2Janux Therapeutics, Inc.
- Follicular helper T (TFH) cells specific to SARS-COV-2 virus15 Sep 2026US 12,734,232 B2The University of Osaka
- Exosomes comprising coronavirus-derived antigen protein or gene encoding same protein, and use of same8 Sep 2026US 12,728,154 B2Ewha University-Industry Collaboration Foundation
- Combination of markers for predicting the response to Vx-0018 Sep 2026US 12,728,158 B2Kriptic Pharmaceuticals Limited
- Mucosal vaccines against tuberculosis8 Oct 2026US 2026/0306604 A1University of Houston System
- A novel non-stoichiometric multi-element adjuvant (nsma) and composition thereof8 Oct 2026US 2026/0306624 A1Magvitae Innovations Inc
- Mutated fragment of vzv glycoprotein e1 Oct 2026US 2026/0295035 A1
- Saponin dmlt adjuvants and related uses1 Oct 2026US 2026/0295037 A1Q-Vant Biosciences, Inc.
- Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns1 Oct 2026US 2026/0297191 A1ImmunoBrain Checkpoint, Inc.
Most cited
By later US patents
- Immunotherapy against several tumors, such as lung cancer, including NSCLC198US 10,071,148 B2Immatics Biotechnologies GmbH · 2018
- Application of mRNA for use as a therapeutic agent for tumorous diseases194US 8,217,016 B2CureVac AG · 2012
- Immunostimulatory combinations138US 7,387,271 B23M Innovative Properties Company · 2008
- Immunotherapy against several tumors, such as lung cancer, including NSCLC131US 9,943,579 B2Immatics Biotechnologies GmbH · 2018
- Immunogenic epitope for immunotherapy117US 8,080,634 B2Immatics Biotechnologies GmbH · 2011